Cipla Share Price Rises 3.79% on Apr 11; Gets USFDA Approval for Cancer Drug Paclitaxel

Cipla Limited has announced that it received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, on April 10, 2025.  

Protein-bound Paclitaxel 

This product is a generic therapeutic equivalent of Bristol Myers Squibb’s Abraxane®, and is AB-rated, confirming its bioequivalence to the reference drug. 

The drug, known as Protein-bound Paclitaxel, is used in the treatment of several severe cancer types including metastatic breast cancer, non-small cell lung cancer (NSCLC), and metastatic adenocarcinoma of the pancreas. Cipla plans to launch this product in the first half of FY2025–26 in the United States, expanding its oncology portfolio and strengthening its footprint in the U.S. generic injectables market. 

Read: Can You Buy a ₹56,000 Phone on EMI with a ₹30,000 Credit Limit?

About Cipla Ltd 

Cipla is a global pharmaceutical company with a focus on complex generics and expanding its portfolio across key markets, including India, South Africa, North America, and other regulated and emerging regions. With 46 manufacturing facilities worldwide, Cipla produces over 1,500 products across 50+ dosage forms, leveraging advanced technology platforms to serve more than 80 global markets. 

On April 11, 2025, Cipla share price opened at ₹1,460.00, up from its previous close of ₹1,415.60. At 10:00 AM, the share price of Cipla was trading at ₹1,469.30, up by 3.79% on the NSE. 

Conclusion 

This approval reaffirms Cipla’s focus on affordable oncology solutions and enhances its presence in the U.S. cancer care segment. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

 Investments in the securities market are subject to market risks, read all the related documents carefully before investing.